| 产品编号 | bs-3860R |
| 英文名称 | CHRDL2 |
| 中文名称 | 乳腺肿瘤新因子1抗体 |
| 别 名 | BNF1; Breast tumor novel factor 1; CHL2; chordin like 2; Chordin like protein 2 precursor; Chordin related protein 2; CRDL2_HUMAN. |
| 研究领域 | 肿瘤 免疫学 生长因子和激素 血管内皮细胞 |
| 抗体来源 | Rabbit |
| 克隆类型 | Polyclonal |
| 交叉反应 | Mouse,Rat (predicted: Human,Cow,Sheep) |
| 产品应用 | WB=1:500-2000, IHC-P=1:100-500, IHC-F=1:100-500, IF=1:100-500, ELISA=1:5000-10000
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理论分子量 | 45kDa |
| 细胞定位 | 分泌型蛋白 |
| 性 状 | Liquid |
| 浓 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human CHRDL2: 351-429/429 |
| 亚 型 | IgG |
| 纯化方法 | affinity purified by Protein A |
| 缓 冲 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存条件 | Shipped at 4℃. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. |
| 注意事项 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 产品介绍 |
CHRDL2 is a novel chordin like protein that can act as a BMP antagonist. A
member of the chordin family of proteins, it contains a signal peptide and
three CR (cysteine-rich repeat) domains. When expressed as a recombinant
protein it is secreted and binds to activin A, but not to BMP-2, -4, -6. Differential expression has been detected in developing chondrocytes, myoblasts, osteoblasts, and osteoarthritic joints. Complex alternative splicing of CHRDL2 potentially results in distinct isoforms that differ at their C termini, in the expression of signal peptide, and in the content of CR domains. CHRDL2 was originally characterized as a novel protein exclusively expressed in breast, lung, and colon tumors. Function: May inhibit BMPs activity by blocking their interaction with their receptors. Has a negative regulator effect on the cartilage formation/regeneration from immature mesenchymal cells, by preventing or reducing the rate of matrix accumulation (By similarity). Implicated in tumor angiogenesis. May play a role during myoblast and osteoblast differentiation, and maturation. Subunit: Interacts with GDF5 (By similarity). May interact with BMP2, BMP4, BMP5, BMP6, BMP7 and INHBA. Subcellular Location: Isoform 1: Secreted (Potential). Isoform 2: Secreted (Potential). Isoform 3: Cytoplasm (Potential). Isoform 4: Cytoplasm (Potential). Isoform 5: Cytoplasm (Potential). Tissue Specificity: Highly expressed in uterus. Moderately expressed in heart, liver, prostate, testis and ovary. Weakly expressed in skeletal muscle, kidney, spleen, small intestine and colon. Expressed in the secretory epithelial cells of uterine endometrium, fallopian tubes, endocervical glands, bladder and prostate, as well as the transitional epithelium of the urinary bladder, and in bone osteoblasts (at protein level). In normal cartilage, expression was confined in a few chondrocytes in the superficial zone as well as in the middle zone. In diseased cartilage coming from osteoarthritic patients, expression was limited to the middle zone of chondrocytes. Isoform 1 and isoform 2 are expressed in fetal cerebellum and heart, while only isoform 2 is detected in fetal spleen. Isoform 2 present in plasma. Post-translational modifications: Phosphorylation sites are present in the extracellular medium. Isoform 2 is phosphorylated on Ser-402. Similarity: Contains 3 VWFC domains. SWISS: Q6WN34 Gene ID: 25884 Database links: Entrez Gene: 25884 Human Omim: 613127 Human SwissProt: Q6WN34 Human Unigene: 432379 Human
CHRDL2原来主要用于乳腺癌的研究，近年来研究发现在肿瘤中也有发现，目前在肺癌，结肠肿瘤的研究中应用较多。 |
| 产品图片 |
Sample:
Uterus (Rat) Lysate at 40 ug Testis (Rat) Lysate at 40 ug Primary: Anti- CHRDL2 (bs-3860R) at 1/1000 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 45 kD Observed band size: 45 kD 
Sample:
Uterus(Mouse) Lysate at 40 ug Primary: Anti- CHRDL2 (bs-3860R) at 1/1000 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 45 kD Observed band size: 45 kD |
| 1、抗体溶解方法 | |
| 2、抗体修复方式 | |
| 3、常用试剂的配制 | |
| 4、免疫组化操作步骤 | |
| 5、免疫组化问题解答 | |
| 6、Western Blotting 操作步骤 | |
| 7、Western Blotting 问题解答 | |
| 8、关于肽链的设计 | |
| 9、多肽的溶解与保存 | |
| 10、酶标抗体效价测定程序 | |
